Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $79K rose 3.9% year over year, ahead of the +2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +49.5% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3.9% holds above the trailing-twelve-month pace of +2.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 311K USD
- Year-over-year change
- +1.6%
- 4-year CAGR
- +55.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 311K | +1.6% |
| FY2024 | 2024-12-31 | 306K | -1.3% |
| FY2023 | 2023-12-31 | 310K | +233.3% |
| FY2022 | 2022-12-31 | 93K | +75.5% |
| FY2021 | 2021-12-31 | 53K | — |
Depreciation & Amortization vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.6% is the 2nd highest of 9, against a peer median of -8.9%.
- Over three fiscal years its annual growth of +49.5% compares with a peer median of +16.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.27M USD | +111.9% | +16.3% | 3.7% | |
| LTM Aug 2026 | $15.87M USD | -14.3% | +20.4% | 2.3% | |
| LTM Mar 2026 | €12.05M EUR | -2.4% | +19.6% | 32.3% | |
| LTM Jun 2026 | $10.17M USD | -10.7% | +6.1% | 9.7% | |
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| LTM Mar 2026 | $3.59M USD | — | — | — | |
| LTM Mar 2026 | $1.98M USD | -3.3% | +34.1% | 9.2% | |
| LTM Mar 2026 | $1.84M USD | -31.3% | -31.1% | 2.3% | |
| LTM Mar 2026 | $645K USD | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $314K USD | +2.6% | +49.5% | — | |
| LTM Dec 2025 | $0 USD | — | -0.5% | 0.0% | |
| Peer median (excluding CGEM) | — | -8.9% | +16.3% | 4.1% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (67.49M) | 109.2M | (153.16M) | (167.58M) | (219.88M) |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| Deferred Income Tax | 3.1M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.38M | 27.96M | 30.44M | 37.82M | 36.04M |
| Change in Working Capital | (3.54M) | 11.18M | (339K) | (389K) | 14.08M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.84M) | (509K) | (167K) | (812K) | (839K) |
| Other Working Capital | 1.29M | 11.69M | (172K) | 423K | 14.92M |
| Other Non-Cash Items | 67K | (275.09M) | (11.52M) | (15.47M) | (6.31M) |
| Operating Cash Flow | (43.43M) | (126.66M) | (134.28M) | (145.3M) | (175.75M) |
| Capital Expenditures | (589.23K) | (1.13M) | (208K) | 0 | (49K) |
| Acquisitions (Net) | 923K | 275M | (36.01K) | 0 | 0 |
| Purchases of Investments | (525.81M) | (377.92M) | (373.38M) | (721.13M) | (236.53M) |
| Sales of Investments | 192.04M | 352.93M | 409.4M | 584.82M | 416.57M |
| Other Investing Activities | (333.78K) | 91K | 36.01K | 0 | 0 |
| Investing Cash Flow | (333.78M) | 248.98M | 35.81M | (136.31M) | 179.99M |
| Debt Repayment | 0 | (2.2M) | 1.83M | 0 | 0 |
| Common Stock Issued | 267.27M | 8.4M | 38.39M | 262.65M | 1.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | (32.13M) | 538K | 3.54M | 0 |
| Financing Cash Flow | 268.78M | (25.93M) | 40.75M | 266.19M | 1.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (108.42M) | 96.38M | (57.72M) | (15.43M) | 5.33M |
| Free Cash Flow | (44.02M) | (127.8M) | (134.48M) | (145.3M) | (175.8M) |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.